Vitro Biopharma CEO Accepts the Frost & Sullivan 2014 Stem Cell Tools & Technology Innovation Leadership Award

Our CEO recently attended the awards ceremony in San Jose California to formally accept the Best in Practice Technology Innovation Leadership award for Stem Cell Tools and Technology.  The event was attended by 32 companies representing awards given for Economic Development and New Product Innovation.  Business sectors that were honored by awards included Communications & […]

October 4th, 2014|

Vitro Biopharma CEO Accepts the Frost & Sullivan 2014 Stem Cell Tools & Technology Innovation Leadership Award

Our CEO recently attended the awards ceremony in San Jose California to formally accept the Best in Practice Technology Innovation Leadership award for Stem Cell Tools and Technology.  The event was attended by 32 companies representing awards given for Economic Development and New Product Innovation.  Business sectors that were honored by awards included Communications & […]

October 4th, 2014|

Efficacy of Stem Cell Therapy for Stroke Demonstrated in Landmark Study using Vitro Biopharma Stem Cells & Media

Golden, Colorado—September 9, 2014—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma announced the publication of a research study using its stem cells to treat an animal model of stroke.  University of Illinois College of Medicine at Peoria (UICOMP) researchers, led by Dr. Krishna Kumar Veeravalli recently published a study showing a prominent reduction in brain […]

September 9th, 2014|

Vitro Biopharma Appoints Jeff Liter to its Board of Directors

Golden, Colorado—August 20, 2014—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma is pleased to announce the appointment of Mr. Jeff Liter to its Board of Directors.  Mr. Liter is a versatile business executive who has consistently delivered profitable revenue growth across multiple businesses, industries and geographic regions. He presently serves as the Chief Operating Officer […]

August 20th, 2014|

Vitro Biopharma Announces Strong Third Quarter Revenue & Positioning for Further Growth

Golden, Colorado—August 12, 2014—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced continued revenue growth in its third fiscal quarter of 2014 and developments to further increase revenue.   Total revenues increased over four-fold in the first nine months of 2014 compared to the same period in 2013 from increased product sales and revenues from contract […]

August 12th, 2014|

Vitro Biopharma Receives Frost & Sullivan Technology Innovation Leadership Award: 2014 Best Practices for Stem Cell Tools & Technology in North America

Golden, Colo.—July 9, 2014—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, is pleased to announce receipt of a prestigious award from Frost & Sullivan. The award is based on independent analysis of competing companies’ commitment to innovation, commercial success, application diversity and fulfillment of unmet needs. Vitro Biopharma out-ranked competing firms in all areas evaluated.

Cecilia […]

July 28th, 2014|

Vitro Biopharma Announces Advances in Stem Cell Therapy without Transplants

Golden, Colorado—June 10, 2014—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, has been pursuing the determination of therapeutic benefits derived from activation of adult stems residing within the human body. This approach is advantageous over transplantation since many of the complications are overcome including, effects of in-vitro stem cell expansion, effects of allogeneic cells and […]

June 10th, 2014|

Stem Cell Therapy without Stem Cell Transplants Part II: New Paradigm for Treatment and Performance Enhancement

While stem cell transplants are clearly warranted for certain conditions including leukemia & lymphoma, there is growing evidence that activation of endogenous stem cells is an emerging approach to therapy. Latent stem cells require activation of specific biological signaling pathways including mobilization through chemokine signaling, proliferation/differentiation through Wnt pathway activation and epigenetic modulation of specific […]

June 6th, 2014|

Stem Cell Therapy without Stem Cell Transplants Part I: Current Status

Transplantation of hematopoietic stem cells has been widely used as an approved treatment of leukemia, lymphoma and certain autoimmune conditions for the past fifty years.  Other adult stem cells have demonstrated safety and efficacy in pre-clinical research and clinical trials.  Mesenchymal stem cell transplants have been most widely studied in animals, especially horses & dogs, […]

June 6th, 2014|

Vitro Biopharma Revenues Continue to Accelerate Towards Profitability

Golden, Colorado—May 6, 2014—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced completion of its second fiscal quarter.  Revenues continue to show strong growth and the Company projects near-term attainment of profitable operations.  Total revenues increased three-fold (300%) in the first six months of 2014 compared to the same period in 2013 from increased product […]

May 6th, 2014|